newborn screening programme

Duchenne muscular dystrophy

We are currently accepting public comments on this condition.
Closing date: 8th October 2021.
Scheduled UK NSC meeting date: October 2021.

The muscular dystrophies are a group of genetic disorders. They cause progressive weakness. Some are severe and limit life expectancy whilst others relatively mild. Some people with the disorder may have no family history of a similar condition.

UK NSC screening recommendation Based on the last UK NSC review of this condition that occurred in November 2016.

Screening is not currently recommended for this condition.

Newborn screening for Duchenne Muscular Dystrophy (DMD) is not recommended because:

  • there is not a reliable test
  • the best age to start treatment is not known
  • there is a lack of evidence that screening and early treatment would improve the long term health of babies

Supporting documents from the 2016 review

Evidence summary Duchenne Muscular Dystrophy (2016)
This document provides the evidence on which the current UK NSC recommendation is based.

UK NSC coversheet & consultation responses Duchenne Muscular Dystrophy (2016)
This document summarises the review process including the public consultation comments.

Review cycle

Date previous review completed: 2016

Next review estimated to be completed: 2021 to 2022.

To see previous evidence reviews, visit the UK NSC archive.

Organisations interested in Duchenne muscular dystrophy

These organisations have expressed interest in this recommendation and may submit responses to evidence reviews.

List of organisations

If you think your organisation should be added, please contact us. More information for organisation can be found in appendix C of the UK NSC evidence review process.